Publications by authors named "Laura Q M Chow"

40Publications

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.

Br J Cancer 2020 Oct 5. Epub 2020 Oct 5.

Departments of Thoracic/Head and Neck Medical Oncology and Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-020-01099-7DOI Listing
October 2020

Head and Neck Cancer. Reply.

Authors:
Laura Q M Chow

N Engl J Med 2020 05;382(20):e57

University of Texas at Austin, Austin, TX

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc2001370DOI Listing
May 2020

Head and Neck Cancer.

Authors:
Laura Q M Chow

N Engl J Med 2020 01;382(1):60-72

From the Division of Medical Oncology, Department of Medicine, University of Washington, Thoracic, Head, and Neck Malignancies, Seattle Cancer Care Alliance, and Fred Hutchinson Cancer Research Center - all in Seattle.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMra1715715DOI Listing
January 2020

Wound Complications in Head and Neck Squamous Cell Carcinomas After Anti-PD-1 Therapy.

Laryngoscope 2019 12 10;129(12):E428-E433. Epub 2019 May 10.

Department of Medicine, Division of Medical Oncology, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington, Seattle, Washington.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/lary.27902
Publisher Site
http://dx.doi.org/10.1002/lary.27902DOI Listing
December 2019

Management of treatment-related toxicities in advanced medullary thyroid cancer.

Cancer Treat Rev 2018 May 22;66:64-73. Epub 2018 Apr 22.

Dana-Farber Cancer Institute, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.04.007DOI Listing
May 2018

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.

Clin Cancer Res 2017 09;23(17):4959-4969

The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-3065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735844PMC
September 2017

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

J Clin Oncol 2017 Aug 13;35(24):2781-2789. Epub 2017 Jun 13.

Solange Peters, Centre Hospitalier Universitaire Vaudois, Lausanne; Martin Früh, Kantonsspital St Gallen, St Gallen, Switzerland; Scott Gettinger, Yale Cancer Center, New Haven, CT; Melissa L. Johnson, Sarah Cannon Research Institute, Nashville, TN; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; Marina C. Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Daniel Christoph, Universitätsklinikum Essen, and the Ruhrlandklinik, Universität Duisburg-Essen, Essen; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany; Chee Keong Toh, National Cancer Centre, Singapore, Singapore; Naiyer A. Rizvi and Jamie E. Chaft, Memorial Sloan Kettering Cancer Center; Jamie E. Chaft, Weill Cornell Medical College, New York, NY; Enric Carcereny Costa, Catalan Institute of Oncology Badalona, Badalona; Luis Paz-Ares, Hospital Universitario Doce de Octubre & IIS i+12, CNIO, Ciberonc and Universidad Complutense, Madrid; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Jyoti D. Patel, University of Chicago, Chicago, IL; Laura Q.M. Chow, University of Washington, Seattle, WA; Marianna Koczywas, City of Hope, Duarte; Zhengrong Li, Jiaheng Qiu, Marcin Kowanetz, Simonetta Mocci, Geetha Shankar, and Alan Sandler, Genentech, South San Francisco, CA; Cheryl Ho, Vancouver Centre, BC Cancer Agency, Vancouver, British Columbia; Jeffrey Rothenstein, R.S. McLaughlin Durham Regional Cancer Centre, Oshawa; Frances A. Shepherd, Princess Margaret Cancer Centre/University Health Network and University of Toronto, Toronto, Ontario, Canada; Michel van den Heuvel, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; and Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.9476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562171PMC
August 2017

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

Cancer Treat Rev 2017 Apr 30;55:181-189. Epub 2017 Mar 30.

University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.03.006DOI Listing
April 2017

Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.

Neuro Oncol 2017 01;19(1):i1-i24

Seattle Cancer Center Alliance, Seattle, Washington (M.C.C., C.S.B., V.K.G., S.B., L.Q.M.C.); Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington (C.S.B., V.K.G., L.Q.M.C.); Departments of Neurology and Neurological Surgery, University of Washington, Seattle, Washington (M.C.C.); Division of Medical Oncology, University of Washington, Seattle, Washington (C.S.B., V.K.G., S.B., L.Q.M.C).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/now197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5193029PMC
January 2017

Harnessing the Immune System as a Therapeutic Tool in Virus-Associated Cancers.

JAMA Oncol 2017 Jan;3(1):106-112

Division of Medical Oncology, Department of Medicine, University of Washington, Seattle.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.4574DOI Listing
January 2017

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

J Clin Oncol 2016 11 30;34(32):3838-3845. Epub 2016 Sep 30.

Laura Q.M. Chow, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Robert Haddad, Dana-Farber Cancer Institute, Boston, MA; Shilpa Gupta and Amit Mahipal, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Ranee Mehra, Fox Chase Cancer Center, Philadelphia, PA; Joseph Paul Eder and Barbara Burtness, Yale University Cancer Center, New Haven, CT; Hyunseok Kang, Johns Hopkins University, Baltimore, MD; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Amy Meister, Marisa Dolled-Filhart, Kumudu Pathiraja, and Jonathan D. Cheng, Merck, Kenilworth, NJ; Tanguy Y. Seiwert, The University of Chicago, Chicago, IL; Makoto Tahara, National Cancer Center Hospital East, Kashiwa; Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan; Raanan Berger, Sheba Medical Center, Tel Hashomer; Ravit Geva, Sourasky Medical Center, Tel-Aviv, Israel; Se-Hoon Lee and Bhumsuk Keam, Seoul National University Hospital; Hyun Cheol Chung, Yonsei University College of Medicine, Seoul, Korea; and Chia-Chi Lin, National Taiwan University Hospital, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.1478DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804896PMC
November 2016

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

J Clin Oncol 2016 07 2;34(21):2460-7. Epub 2016 May 2.

Rita Nanda, University of Chicago, Chicago, IL; Laura Q.M. Chow, University of Washington, Seattle, WA; E. Claire Dees, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Raanan Berger, Sheba Medical Center, Tel Hashomer; Ravit Geva, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Lajos Pusztai, Yale University School of Medicine, New Haven, CT; Kumudu Pathiraja, Gursel Aktan, Jonathan D. Cheng, and Vassiliki Karantza, Merck & Co., Kenilworth, NJ; and Laurence Buisseret, Université Libre de Bruxelles, Bruxelles, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.8931DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816000PMC
July 2016

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.

Oncologist 2015 Jul 11;20(7):812-22. Epub 2015 Jun 11.

Levine Cancer Institute, Charlotte, North Carolina, USA; University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0422DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492230PMC
July 2015

Ceritinib in ALK-rearranged non-small-cell lung cancer.

N Engl J Med 2014 Mar;370(13):1189-97

From Massachusetts General Hospital, Boston (A.T.S., J.A.E.); Seoul National University Hospital, Seoul, South Korea (D.-W.K.); Fox Chase Cancer Center, Philadelphia (R.M.); National Cancer Center and Genome Institute of Singapore, Singapore (D.S.W.T.); Vall d'Hebron University, Barcelona (E.F.); University of Washington, Seattle (L.Q.M.C.); University of Colorado, Denver (D.R.C.); University Hospital KU Leuven, Leuven, Belgium (J.V.); Huntsman Cancer Institute, Salt Lake City (S.S.); Istituto Europeo di Oncologia (T.D.P.) and Istituto di Ricovero e Cura a Carattere Scientifico Istituto Clinico Humanitas (A.S.) - both in Milan; Memorial Sloan-Kettering Cancer Center, New York (G.J.R.); Peter MacCallum Cancer Center, Melbourne, VIC, Australia (B.J.S.); Center for Integrated Oncology, University Hospital Cologne, Cologne (J.W.), Thoraxklinik, University of Heidelberg, Translational Lung Research Center Heidelberg, German Center for Lung Research (M.T.), and German Cancer Consortium (M.S.), Heidelberg, and University Duisburg-Essen, Essen (M.S.) - all in Germany; Princess Margaret Cancer Center, Toronto (G.L.); and Novartis Institutes for BioMedical Research, Cambridge, MA (Y.Y.L., M.G., A.L.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1311107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079055PMC
March 2014

Adjuvant Radiotherapy for Stages II and III Resected Thymoma: A Single-institutional Experience.

Am J Clin Oncol 2016 06;39(3):223-7

*Department of Radiology ‡Seattle Cancer Care Alliance §Department of Pathology ¶Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA †The Wistar Institute, Philadelphia, PA ∥Department of Radiation Oncology University of Washington, University of Minnesota, Minneapolis, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000044DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5199721PMC
June 2016

Neutron radiotherapy for adenoid cystic carcinoma of the lacrimal gland.

Ophthalmic Plast Reconstr Surg 2013 Jul-Aug;29(4):256-60

University of Washington Medical Center, Seattle, Washington 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IOP.0b013e318295f99bDOI Listing
January 2014

Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.

Authors:
Laura Q M Chow

Am Soc Clin Oncol Educ Book 2013

From the Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.e280DOI Listing
November 2015

Sunitinib: from rational design to clinical efficacy.

J Clin Oncol 2007 Mar;25(7):884-96

Department of Medical Oncology, University of Colorado Health Sciences Center, Aurora, CO 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2006.06.3602DOI Listing
March 2007